APM
GMAB icon

Avidity Partners Management’s Genmab GMAB Stock Holding History

Avidity Partners Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-433,100
Closed -$8.48M – 67
2025
Q1 		$8.48M Buy
+433,100
New +$9.08M 1.62% 21

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Avidity Partners Management's GMAB Position: Q2 2026 in Review

Avidity Partners Management held its Genmab (GMAB) position steady in Q2 2026 at 50,000 shares worth $1.37M. The position accounts for 0.22% of the portfolio, ranked #33.

Avidity Partners Management first reported a position in GMAB in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.4M in Q2 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Avidity Partners Management held 50,000 shares of Genmab worth $1.37M as of Q2 2026.
  • Avidity Partners Management left its Genmab share count unchanged in Q2 2026.
  • Genmab made up 0.22% of Avidity Partners Management's portfolio in Q2 2026, its #33 holding.
  • Avidity Partners Management first reported a position in Genmab in Q2 2025 and has held it in 5 quarters since.
  • Avidity Partners Management's Genmab position peaked at $13.4M in Q2 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.